skip to main content

KPS vs ECOG — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardSupportive & Palliative OncologyKPS vs ECOGSCE Medical Oncology

An adult develops metastatic nasopharyngeal carcinoma 18 months after definitive chemoradiotherapy. The recurrence is not amenable to curative surgery or radiotherapy, and no systemic treatment has been given for recurrent disease. Which regimen is specifically licensed for this first-line setting in the current UK Tevimbra SmPC?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Tislelizumab with gemcitabine and cisplatin

Explanation lettering: B = shown as A · A = shown as B · D = shown as C · C = shown as D

B is correct: the UK Tevimbra SmPC licenses tislelizumab with gemcitabine and cisplatin for first-line treatment of adults with metastatic nasopharyngeal carcinoma, or recurrent disease not amenable to curative surgery or radiotherapy. A substitutes a head-and-neck regimen that is not the licensed NPC combination. C uses the squamous-NSCLC chemotherapy backbone. D omits the required first-line chemotherapy partners, and E substitutes a gastrointestinal fluoropyrimidine-oxaliplatin backbone. NHS commissioning should still be checked separately from the marketing authorisation.

Reference: Tevimbra UK summary of product characteristics (Current UK SmPC, accessed 1 August 2026): https://www.medicines.org.uk/emc/product/102372/smpc